---
title: "Novartis pelacarsen cuts Lp(a) but fails to reduce major cardiovascular events"
id: "stat-news-0-stat-failure-of-novartis-lp-a-drug-raises-questions-about-cardiovascular"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-failure-of-novartis-lp-a-drug-raises-questions-about-cardiovascular"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/11/07/aha-conference-news-novartis-lp-a-pelacarsen-heart-disease-trial-mystery/?utm_campaign=rss"
published_at: "2026-11-07T14:50:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Novartis pelacarsen cuts Lp(a) but fails to reduce major cardiovascular events
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-failure-of-novartis-lp-a-drug-raises-questions-about-cardiovascular
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/11/07/aha-conference-news-novartis-lp-a-pelacarsen-heart-disease-trial-mystery/?utm_campaign=rss)
- **Published At:** 2026-11-07T14:50:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The Phase 3 **HORIZON** trial, funded by Novartis, showed that the antisense therapy **pelacarsen** substantially lowered circulating **Lp(a)** levels but produced no reduction in major cardiovascular outcomes over follow-up of almost five years. - Investigators reported no between-group difference in rates of myocardial infarction, stroke, urgent coronary revascularization, or death in participants randomized to pelacarsen versus placebo. - The study team presented these fuller results at the American Heart Association scientific sessions and published the findings in the **New England Journal of Medicine** the same day. - The article notes that **Lp(a)** is a genetic cardiovascular risk factor present in about one in five people; earlier top-line results signaled biochemical lowering of Lp(a) but an absence of clinical benefit. - Authors and trial leaders characterized the outcome as unexpected; one trial leader said, “This will leave a lot of people scratching their heads.” - The source did not provide detailed trial methodology in this excerpt: specific dosing regimens, sample size, baseline characteristics, statistical endpoints, or prespecified subgroup analyses were not reported in the provided text. - The report raises questions about the strategy of targeting **Lp(a)** to prevent heart attacks and strokes, and it signals the need for careful examination of trial design, patient selection, and potential mechanisms behind the neutral clinical result. - The findings may influence ongoing and planned Lp(a)-lowering programs and debate around biomarkers versus hard clinical outcomes in cardiovascular drug development.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/11/07/aha-conference-news-novartis-lp-a-pelacarsen-heart-disease-trial-mystery/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/07/aha-conference-news-novartis-lp-a-pelacarsen-heart-disease-trial-mystery/?utm_campaign=rss) [research](https://www.statnews.com/topic/research/) [chronic disease](https://www.statnews.com/topic/chronic-disease/) [Cancer](https://www.statnews.com/topic/cancer/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Trust in Science](https://www.statnews.com/trust-in-science/) * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Pharma](https://www.statnews.com/category/pharma/) # Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy ## ‘This will leave a lot of people scratching their heads,’ says trial leader * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/11/07/aha-conference-news-novartis-lp-a-pelacarsen-heart-disease-trial-mystery/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_450283499_Editorial_Use_Only-645x645.jpeg) Adobe ![](https://www.statnews.com/wp-content/uploads/2021/02/liz-c-avatar-small2-80x80.png) ![](https://www.statnews.com/wp-content/uploads/2021/02/matt-h-avatar-small2-80x80.png) By [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) and [Matthew Herper](https://www.statnews.com/staff/matthew-herper/) Nov. 7, 2026 ![](https://www.statnews.com/wp-content/uploads/2021/02/liz-c-avatar-small2-80x80.png) [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) 1. [](https://x.com/cooney_liz "X") elizabeth.cooney@statnews.com Liz covers cardiovascular and metabolic disease, asking [why we’re not doing better](https://www.statnews.com/2024/10/15/cardiovascular-disease-rising-experts-on-causes/) or even [losing ground](https://www.statnews.com/2024/04/24/heart-failure-deaths-decline-undone/) against the world’s leading killer. Send tips on Signal at LizC.22. ![](https://www.statnews.com/wp-content/uploads/2021/02/matt-h-avatar-small2-80x80.png) [Matthew Herper](https://www.statnews.com/staff/matthew-herper/) 1. [](https://x.com/matthewherper "X") matthew.herper@statnews.com Matthew Herper covers medical innovation — both its promise and its perils. CHICAGO — Lipoprotein(a), a genetic risk factor for cardiovascular disease carried by 1 in 5 people, is the target of novel therapies trying to cut down heart attacks, strokes, and deaths in those at risk. The growing field of research aimed at the particle took a hit [earlier this year](https://www.statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/) when top-line results showed an experimental drug reduced Lp(a) but failed to lower serious outcomes. More details of the study, funded by Novartis, were revealed Saturday at the American Heart Association’s scientific sessions and published simultaneously in the [New England Journal of Medicine](http://www.nejm.org/doi/full/10.1056/NEJMoa2610159). Advertisement In the Phase 3 trial, the drug pelacarsen dramatically lowered Lp(a), a mashup of lipids and proteins that at high levels can heighten the risk of severe heart problems. But despite lower Lp(a), the HORIZON trial showed no difference in heart attacks, strokes, urgent coronary revascularization, or deaths in participants followed for almost five years who were randomly selected to take the drug or a placebo. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [cardiovascular disease](https://www.statnews.com/topic/cardiovascular-disease/), [Clinical trials](https://www.statnews.com/topic/clinical-trials/), [drug development](https://www.statnews.com/topic/drug-development/), [genetics](https://www.statnews.com/topic/genetics/), [research](https://www.statnews.com/topic/research/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/liz-c-avatar-small2-80x80.png) [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) 1. [](https://x.com/cooney_liz "X") 2. [](https://bsky.app/profile/elizabethcooney.bsky.social "Bluesky") 3. Cardiovascular Disease Reporter 1. [](https://x.com/cooney_liz "X") 2. [](https://bsky.app/profile/elizabethcooney.bsky.social "Bluesky") 3. Liz covers cardiovascular and metabolic disease, asking [why we’re not doing better](https://www.statnews.com/2024/10/15/cardiovascular-disease-rising-experts-on-causes/) or even [losing ground](https://www.statnews.com/2024/04/24/heart-failure-deaths-decline-undone/) against the world’s leading killer. Send tips on Signal at LizC.22. 2. ![](https://www.statnews.com/wp-content/uploads/2021/02/matt-h-avatar-small2-80x80.png) [Matthew Herper](https://www.statnews.com/staff/matthew-herper/) 1. [](https://x.com/matthewherper "X") 2. Senior Writer, Medicine, Editorial Director of Events 1. [](https://x.com/matthewherper "X") 2. Matthew Herper covers medical innovation — both its promise and its perils. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_1874804219-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Beyond statins, one drug lowered heart attack risk by 20%](https://www.statnews.com/2026/11/05/repatha-vs-zetia-cholesterol-study-heart-attack-risk/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_387040854-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories](https://www.statnews.com/2026/11/07/aha-2026-conference-novo-nordisk-zeus-trial-ziltivekimab-results/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/11/F0367611-Adeno-associated_virus_illustration-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [New tumor cases show common gene therapy tool can come with risk](https://www.statnews.com/2026/11/06/novartis-zolgensma-gene-therapy-tumor-risk/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/kratomexplainer-80x80.jpg) [Most people haven’t heard of kratom. What is it, and who’s using it?](https://www.statnews.com/2026/11/06/what-is-kratom-addiction-risks-explained-7-oh/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/Revmed_campus2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Revolution Medicines’ pancreatic cancer drug has stunning commercial debut](https://www.statnews.com/2026/11/05/rasonque-revolution-medicines-pancreatic-cancer-commercial-launch/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/10/STATatHLTH_Wordpress_CalendarImage-80x80.jpg) STAT@hlth. A Dose of Reality on EHRs and AI In-person Nov 18 ](https://www.statnews.com/event/stathlth-a-dose-of-reality-on-ehrs-and-ai/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/BTE2027_Wordpress_CalendarImage-80x80.jpg) 2027 Breakthrough Summit East New York City, NY Mar 18 ](https://www.statnews.com/event/2027-stat-breakthrough-summit-east/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/11/AdobeStock_1874804219-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Beyond statins, one drug lowered heart attack risk by 20%](https://www.statnews.com/2026/11/05/repatha-vs-zetia-cholesterol-study-heart-attack-risk/) 2. ![](https://www.statnews.com/wp-content/uploads/2021/05/ks051621_SMA_31-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy](https://www.statnews.com/pharmalot/2026/11/05/novartis-sma-zolgensma-tumor-case-reports/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/Revmed_campus2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Revolution Medicines’ pancreatic cancer drug has stunning commercial debut](https://www.statnews.com/2026/11/05/rasonque-revolution-medicines-pancreatic-cancer-commercial-launch/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/11/GettyImages-2302607354-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Democrats win power to push back on Trump’s health care moves](https://www.statnews.com/2026/11/03/midterm-elections-what-democratic-control-senate-means-healthcare/) 5. ![](https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and more](https://www.statnews.com/pharmalot/2026/11/04/cvs-plans-to-split-up-fda-inspections-in-india-and-china/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health Health November 7, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories ](https://www.statnews.com/2026/11/07/aha-2026-conference-novo-nordisk-zeus-trial-ziltivekimab-results/) By [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech November 6, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: New tumor cases show common gene therapy tool can come with risk ](https://www.statnews.com/2026/11/06/novartis-zolgensma-gene-therapy-tumor-risk/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout November 6, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Amgen’s Repatha linked to fewer heart attacks ](https://www.statnews.com/2026/11/06/biotech-news-amgen-repatha-linked-to-fewer-heart-attacks/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot November 5, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy ](https://www.statnews.com/pharmalot/
## Related Clinical Research

- [Cardiologist questions STREAM trial findings on deprescribing statins in older adults](https://medichelpline.com/clinical-feed/stat-news-1-opinion-stat-i-m-a-cardiologist-i-m-a-little-puzzled-about-the-blockbuster-new.md)
- [Watchman cardiac implant: clinicians raise questions as Boston Scientific intensifies sales push](https://medichelpline.com/clinical-feed/stat-news-1-stat-doctors-have-questions-about-the-watchman-boston-scientific-has-a-sales.md)
- [Impact of Nighttime Light Exposure on Heart Health and Disease Risk](https://medichelpline.com/clinical-feed/medical-news-today-0-nighttime-light-exposure-may-alter-the-heart-and-increase-disease-risk.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.